[{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CAMYO-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"myNEO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"myNEO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"myNEO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bisantrene DiHCl","moa":"FTO protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"},{"orgOrder":0,"company":"Cellistic","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BP2202","moa":"BCMA receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellistic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellistic \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellistic \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATB Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATB Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"ATB Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"4","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Complix","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ I-Mab Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Complix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MCL1","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ Inapplicable"},{"orgOrder":0,"company":"Ncardia","sponsor":"Kiniciti","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ncardia \/ Kiniciti","highestDevelopmentStatusID":"4","companyTruncated":"Ncardia \/ Kiniciti"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The collaboration aims to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials.

                          Product Name : BP2202

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 13, 2024

                          Lead Product(s) : BP2202

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : BrightPath Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : EQT Life Sciences

                          Deal Size : $56.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

                          Product Name : RC220

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 07, 2023

                          Lead Product(s) : Bisantrene DiHCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Race Oncology

                          Deal Size : $1.0 million

                          Deal Type : Agreement

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CAMYO-01 is a novel off-the-shelf cancer vaccine, which is incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.

                          Product Name : CAMYO-01

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 25, 2023

                          Lead Product(s) : CAMYO-01

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA techn...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 24, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Fortress Investment Group

                          Deal Size : $10.5 million

                          Deal Type : Private Placement

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 15, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Kiniciti

                          Deal Size : $60.0 million

                          Deal Type : Partnership

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 03, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : I-Mab Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 31, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank